Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Dear Editor, Patient-specific induced pluripotent stem (iPS) cells, generated from somatic cells of disease-affected individuals, hold a tremendous potential for studying disease mechanisms and for drug screening approaches using cell types previously not available (Yamanaka, 2008). Fragile-X (FX) syndrome belongs to the autism spectrum disorders, and is the most common cause of inherited mental retardation with the prevalence of 1/3600 (Crawford et al., 2001). It is nearly always caused by silencing of the FMR1 gene due to abnormal CGG repeat expansions in the 5′-UTR of the gene (Verkerk et al., 1991). Abnormal CGG repeat expansion of over 200 repeats leads to transcriptional silencing and CpG methylation of the gene 5′-UTR and the gene promoter (Sutcliffe et al., 1992). The silencing of the FMR1 gene and the heterochromatinization of the gene promoter were shown to be developmentally dependent (Eiges et al., 2007). In undifferentiated human FX embryonic stem cells (FX-ES cells) derived from affected blastocyst-stage embryos, FMR1 is expressed and gene silencing occurs only upon differentiation (Eiges et al., 2007). Recently, we have generated 11 FX-iPS cell lines from three different FX patients (Urbach et al., 2010). In FX-iPS cells, and contrary to FX-ES cells, the gene is transcriptionally silent both in the pluripotent and differentiated states (Urbach et al., 2010). The absence of FMR1 expression in FX-iPS cells is accompanied by DNA methylation and histone modifications indicative of heterochromatin in the gene promoter (Urbach et al., 2010). Although FX-iPS cells cannot recapitulate the developmentally dependent silencing of FMR1, they represent a unique genetic model system that harbors a completely silent FMR1 locus to study disease phenotypes, and for potential drug screening using the most suitable cells in the context of the disease and the affected individual. Here, we wished to evaluate the reactivation of FMR1 in FX-iPS cells and their differentiated neuronal derivatives by epigenetic modulating drugs. We set out to investigate the ability of several chromatin remodeling drugs to reactivate FMR1 gene expression. Histone deacetylase inhibitor trichostatin-A (TSA) had no significant effect on FMR1 reactivation in FX-iPS cells (Supplementary Figure S1). Next, we wished to evaluate the effect of the demethylating agent 5-azacytidine (5-azaC) on FX-iPS cells. Interestingly, 5-azaC was able to robustly reactivate FMR1 gene expression in FX-iPS cells (Figure 1A and Supplementary Figures S1 and S2). Multiple experiments performed on three FX-iPS cell clones at high concentrations have consistently shown that following 5-azaC administration, FMR1 gene expression is restored, with percent levels ranging between 15% and 45% of the WT levels (Figure 1A). A 10-μM 5-azaC treatment resulted in the highest expression levels of FMR1 (Figure 1A and Supplementary Figure S1). A combination of 5-azaC and TSA treatment culminated in a slight increase in FMR1 expression compared with 5-azaC treatment alone (Supplementary Figure S1). When wild type (WT)-ES cells were treated with 1-μM 5-azaC, FMR1 gene expression did not change (Supplementary Figure S3). The 5-azaC concentrations we used are in accordance with physiological levels found in plasma of patients suffering from solid tumors and hematologic malignancies that were treated with 5-azaC (Rudek et al., 2005). Since neurons are the cell type most afflicted in FX syndrome, we further examined the potential of 5-azaC to restore FMR1 expression in FX-neurons. To generate neurons from FX-iPS cells, we used an established protocol (Schuldiner et al., 2001) for neuronal induction from pluripotent cells. We thoroughly characterized the FX-neurons by various means (Supplementary Figures S4–S6). Following 5-azaC treatment, an increase in FMR1 transcript mRNA level could be detected in FX-neurons, albeit with less efficiency than in FX-iPS cells (Figure 1A). Of note, following 5-azaC treatment, some of the undifferentiated FX-iPS cells underwent cell death or differentiation, as observed by the presence of floating cells, or a change in the morphology of some of the undifferentiated colonies. However, many pluripotent colonies were still present after 7 days of treatment. This intriguing phenomenon was not observed with neuronal cells, suggesting a unique effect of 5-azaC on pluripotent stem cells, possibly by inhibiting DNMT3a and DNMT3b which are predominantly expressed in pluripotent stem cells and not in somatic cells. We next assessed whether FMR1 expression persists after withdrawal of 5-azaC treatment. FX-iPS and FX-neuronal cells were treated for 7 days with 5-azaC, and kept in culture for another 7 days without 5-azaC. As expected, the treatment resulted in reactivation of FMR1 expression, which persists at similar levels even after drug withdrawal, as judged by real-time PCR analysis (Figure 1B). Immunostaining for FMR1 protein (FMRP) showed that 5-azaC treat
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481 · cited 1×
“It is nearly always caused by silencing of the FMR1 gene due to abnormal CGG repeat expansions in the 5′-UTR of the gene (Verkerk et al., 1991).”
BackgroundMarchetto, M. C. N., Carromeu, C., Acab, A., Yu, D., Yeo, G. W., Mu, Y., Chen, G., Gage, F. H., & Muotri, A. R. (2010) · Cell · doi:10.1016/j.cell.2010.10.016 · Cited by 1,329 · cited 1×
“Pluripotent stem cells represent an attractive source to model autism spectrum disorders such as Rett (Marchetto et al., 2010) or FX syndrome (Eiges et al., 2007; Urbach et al., 2010).”
BackgroundFMR1 and the fragile X syndrome: Human genome epidemiology review
Crawford, D. C., Acuña, J. M., & Sherman, S. L. (2001) · Genetics in Medicine · doi:10.1097/00125817-200109000-00006 · Cited by 711 · cited 1×
“Fragile-X (FX) syndrome belongs to the autism spectrum disorders, and is the most common cause of inherited mental retardation with the prevalence of 1/3600 (Crawford et al., 2001).”
BackgroundDNA methylation represses FMR-1 transcription in fragile X syndrome
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680
Yamanaka, S. (2009) · Cell · doi:10.1016/j.cell.2009.03.034 · Cited by 659 · cited 2×
“Patient-specific induced pluripotent stem (iPS) cells, generated from somatic cells of disease-affected individuals, hold a tremendous potential for studying disease mechanisms and for drug screening approaches using cell types previously not available (Yamanaka, 2008).”
BackgroundAcetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells
Coffee, B., Zhang, F., Warren, S. T., & Reines, D. (1999) · Nature Genetics · doi:10.1038/8807 · Cited by 325 · cited 2×
“We further investigated histone modifications indicative of transcriptionally active (H3 tail acetylation and H3 lysine K4 methylation) and repressed (H3 lysine K9 methylation) chromatin states associated with FMR1 silencing in somatic cells of FX individuals (Coffee et al., 1999).”
BackgroundRegulation of molecular pathways in the Fragile X Syndrome: insights into Autism Spectrum Disorders
De Rubeis, S., & Bagni, C. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9087-2 · Cited by 73 · cited 2×
“Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives”
Background
Cited by
Pluripotent stem cells in disease modelling and drug discovery
Avior, Y., Sagi, I., & Benvenisty, N. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.27 · Cited by 592
Self-citationGene × Environment Interactions in Autism Spectrum Disorders: Role of Epigenetic Mechanisms
Tordjman, S., Somogyi, E., Coulon, N., Kermarrec, S., Cohen, D., Bronsard, G., Bonnot, O., Weismann-Arcache, C., Botbol, M., Lauth, B., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00053 · Cited by 283
Park, C.-Y., Halevy, T., Lee, D. R., Sung, J. J., Lee, J. S., Yanuka, O., Benvenisty, N., & Kim, D.-W. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.084 · Cited by 178
“We also have shown that the demethylating agent 5-azacytidine (5-AzaC) can induce reactivation of FMR1 expression in FXS-iPSCs and partial demethylation of the FMR1 promoter, suggesting a direct effect of methylation on the silencing of FMR1 (Bar-Nur et al., 2012).”
BackgroundResultSelf-citationHuman induced pluripotent stem cells for modelling neurodevelopmental disorders
Ardhanareeswaran, K., Mariani, J., Coppola, G., Abyzov, A., & Vaccarino, F. M. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.45 · Cited by 160
Kaufmann, M., Schuffenhauer, A., Fruh, I., Klein, J., Thiemeyer, A., Rigo, P., Gomez-Mancilla, B., Heidinger-Millot, V., Bouwmeester, T., Schopfer, U., et al. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115588287 · Cited by 87
“Although FXSiPSCs cannot mimic the silencing of Fmr1 that occurs during development, they are an useful model system for studying disease mechanisms and for drug screening approaches since they contain a silent Fmr1 locus in the context of the human disease.(15) However, working with scaled-up cultures of iPSC patient…”
Background
Metadata
- Authors
- Bar-Nur, O., Caspi, I., & Benvenisty, N.
- Venue
- Journal of Molecular Cell Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03-19
- Volume
- 4
- Issue
- 3
- Pages
- 180-183
- ISSN
- 1674-2788 (ISSN-L)
- 1759-4685
- OpenAlex
- W2097539804
- Cited by
- 86
- References
- 7
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.